Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Observational Diary Study to Evaluate the Real-World Effectiveness of the Acute Treatment of Migraine With Ubrogepant, When Used in Combination With Atogepant for Prevention

NCT05653986 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05653986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05653986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Observational Diary Study to Evaluate the Real-World Effectiveness of the Acute Treatment of Migraine With Ubrogepant, When Used in Combination With Atogepant for Prevention
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
December 18, 2022
Completion date
August 5, 2024
Enrollment
391 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine